The Power of Cutting-Edge Technology

Agilent is at the forefront of technology innovation to unlock the promise of precision medicine.

The Need for Expertise

At Agilent CDx, dedicated experts collaborate to combine experience with innovation, enabling the full potential of biomarker-driven landmark therapies.

The Future of Targeted Treatment

Agilent is a leading partner to drive clinical utility into proven pathways while helping to enable the next generation of predictive biomarkers.

High-throughput sequencing of novel and evolving biomarker panels, such as TMB and MSI, have the potential to further revolutionize precision medicine.

Established Biomarkers

Emerging Biomarkers

Note:

The above graphic illustrates the range of biomarkers that are actively being studied across a large volume of clinical trials. The featured biomarkers are the top 80 identified based on an analysis of oncology trials mentioning biomarker use on ClinicalTrials.gov, recent publications, and research conducted by a variety of institutions. This list is not intended to be a complete nor comprehensive audit of biomarker research activity, and does not represent nor reflect the specific diagnostic offerings of Agilent Technologies, Inc.

Bar length represents the number of active clinical trials for each biomarker.